Evaluation of Terlipressin and In-Hospital Mortality in the Treatment of Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)

Оценка применения терлипрессина и внутрибольничной летальности при лечении гепаторенального синдрома — острого повреждения почек (HRS-AKI)
Paul Juang, Haley N. Ilcewicz
2026-07-25

Hepatorenal syndrome-acute kidney injuryIn-hospital mortalityMidodrine and octreotideRetrospective cohort studyTerlipressin
Background: Terlipressin is a synthetic vasopressin analogue that is indicated for the treatment of hepatorenal syndrome-acute kidney injury (HRS-AKI) to improve kidney function and haemodynamics. Despite its previous approval in Europe, terlipressin was Food and Drug Administration (FDA)-approved in 2022 in the United States. Historical standards of care, such as midodrine and octreotide (MO), are still used alternatively to terlipressin, and mortality benefit among treatments is unknown. Objective: To examine the effects of terlipressin vs MO in hospitalized patients with HRS-AKI. Methods: This single-centre, retrospective, cohort study was conducted at a large, tertiary academic medical centre. Data were collected from the electronic health record for patients admitted from July 2018 to July 2024. Patients ≥18 years of age admitted with International Classification of Diseases codes for cirrhosis, AKI, and clinical diagnosis of HRS were included. The primary outcome was the incidence of in-hospital mortality between patients receiving terlipressin vs MO. Descriptive statistics and parametric and non-parametric tests were utilized as appropriate. Results: A total of 49 terlipressin patients and 30 MO patients were identified. The rate of in-hospital mortality was lower with terlipressin (n = 12, 24.5%) vs MO (n = 21, 70%) ( P < .001). The mean hospital length of stay (days) was greater with terlipressin than MO (21.4 ± 14 vs 15.5 ± 8.4, P = .081) as was baseline serum creatinine (SCr) (2.94 ± 1.1 vs 1.89 ± 1.2 mg/dL, P < .05). Numerically more patients receiving terlipressin had a response to therapy (21/49 vs 12/30, P = .1033) with a similar decrease in SCr (–34.8 ± 21% vs –36.1 ± 21%, P = .86). The number of days from therapy initiation until the lowest SCr was less with terlipressin vs MO (4.97 ± 3.5 vs 7.92 ± 3.7, P = .02). Conclusion and Relevance: Terlipressin appears to effectively improve renal function and in-hospital mortality in patients with HRS-AKI compared with MO. Terlipressin may be used as a first-line treatment for HRS-AKI or after a trial of MO based on the study’s results.
1
In this single-center retrospective cohort, terlipressin was associated with substantially lower in-hospital mortality than midodrine plus octreotide (24.5% vs 70%; P < .001).
2
Renal response rates were numerically higher with terlipressin, although the difference was not statistically significant (21/49 vs 12/30; P = .1033).
3
Serum creatinine decreased similarly with terlipressin and midodrine plus octreotide (−34.8% vs −36.1%; P = .86).
4
Terlipressin patients had higher baseline serum creatinine and a numerically longer hospital stay, indicating potential baseline differences between treatment groups.
5
Terlipressin-treated patients reached their lowest serum creatinine sooner than patients receiving midodrine plus octreotide (4.97 vs 7.92 days; P = .02).

Hospitalized adult patients with hepatorenal syndrome–acute kidney injury (HRS-AKI) treated with terlipressin or midodrine plus octreotide (MO)

Comparative effects of terlipressin versus MO on in-hospital mortality and renal-function response, including serum creatinine reduction and time to lowest serum creatinine

Publication Details
Publication Date
2026-07-25
Journal
Publisher
ISSN
Cited by
0
Access Type
Author Information
Authors
Paul Juang
Haley N. Ilcewicz
Explore further
Open the scid.ai AI chat with a ready-made request: it will find papers on a similar topic and help build a literature review.
Find similar papers in the chat →
Make a presentation
100%